EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
about
CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant GliomasBiomarkers for glioma immunotherapy: the next generationEGFR Amplification and Glioblastoma Stem-Like CellsEvolving Drug Delivery Strategies to Overcome the Blood Brain Barrier.Strategies to genetically engineer T cells for cancer immunotherapy.History and current state of immunotherapy in glioma and brain metastasis.Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies.Epidermal growth factor receptor and variant III targeted immunotherapy.Immunotherapy for malignant gliomaEmerging immunotherapies for glioblastomaImmunotherapy in glioblastoma: emerging options in precision medicinePrioritization schema for immunotherapy clinical trials in glioblastoma.Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.Chimeric antigen receptor T cells: a novel therapy for solid tumors.Immunotherapeutic advancements for glioblastoma.ErbB-targeted CAR T-cell immunotherapy of cancer.Glioblastoma antigen discovery--foundations for immunotherapy.Stem cell in alternative treatments for brain tumors: potential for gene delivery.CAR T-cell immunotherapy: The path from the by-road to the freeway?Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.Engineered T cells: the promise and challenges of cancer immunotherapy.Developing immunotherapeutic strategies to target brain tumors.Improving vaccine efficacy against malignant gliomaChimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.Immunotherapy approaches in the treatment of malignant brain tumors.Immune and viral therapies for malignant primary brain tumors.Insights into molecular therapy of glioma: current challenges and next generation blueprintSafety of Intra-Arterial Injection With Tumor-Activated T Cells to the Rabbit Brain Evaluated by MRI and SPECT/CT.Biomarkers and therapeutic advances in glioblastoma multiforme.EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence.Targeting Malignant Brain Tumors with Antibodies.CD70, a novel target of CAR T-cell therapy for gliomas.Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma.Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine GliomasCART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors
P2860
Q26740520-E96391F0-8153-4CF9-8F25-1FAA51D2BE78Q26825496-CD2A3E32-CAB5-4D6F-B6F3-F962A54B81D5Q26853549-918B188B-8D27-4C95-BE44-CAA3332EE90AQ28082016-E3B24513-64F4-452C-8956-40BD31D4FEE5Q33655849-F8EF411B-C7DF-4542-813A-3495DEB72E70Q33656811-BF62FC0D-30C4-4B2B-8A09-CA12A11966F9Q33721106-A5BC306C-D98A-4EF2-80D8-8198840BD54EQ34391942-B8B4DE68-DC07-4ACE-91FF-5B5CF9771DE9Q35114086-DCA004D5-A2C5-46FA-9A85-67CCAF3DCF58Q37025105-DA436E08-23D7-435A-BFF9-809554E79A90Q37050960-DDCE9876-0F8A-4F5B-A0D5-BB13D5D76139Q37078999-E83CA41D-F30B-4DCA-94CA-144B912470F3Q37609801-084AB76A-A571-4E4E-9AD0-5845943385A1Q37728639-CC6719B2-8CCB-4510-91AB-80E29F7FD524Q38358124-C7A05643-5864-4DAD-9830-4367F3A80BE8Q38389298-9374CCC6-EABB-4278-B170-E83EDA0D1D68Q38516823-D7AC1357-D223-45B0-916B-91ED617A208FQ38521752-38972CDB-89BC-4297-B5A5-3433FD8058AAQ38632105-C491A1F4-4F56-427E-A334-68FAFB0999ACQ38770555-1A287C2E-4E13-434D-B886-D4415CDF2C36Q38828829-033DA7FB-2523-498A-AA1A-0681D777A565Q38851464-38BB79DA-995A-4234-9898-41854F63FE46Q38953024-C736E745-8806-404D-857D-8F55C473F9FAQ38987239-28D27C27-FDBB-4596-A71E-7E1AD4D70F95Q39016790-1A5268EB-C8DB-483C-816B-C5B7A3EDD766Q39168899-F55F7593-3450-4579-B0E5-E89C9DE6CAB8Q39187306-063A286B-3A89-4357-9693-4DD970762B9CQ39304787-58AE8C36-6006-49BF-8B2E-9B1C3CD37568Q40070524-FF8E1C00-03F4-4ED7-8A61-FFB1D4BC0829Q40089704-9AB2458C-3D7C-4963-9641-1C1D0D9614F5Q42057942-346FB210-0015-496D-ACED-325418505791Q42267793-8F11A781-C56A-42D7-9B63-F144D472EC6FQ48223703-22716E1D-9FE3-44EE-84A6-0F4F449C6F87Q55383661-30F3B94F-0793-4C32-B6BC-CEC27861062DQ55457493-99B7D403-F432-4B26-B2D6-E7CA8DE134CFQ57300937-6B82CDCA-BA4C-4DBD-AED1-8C942A69C130Q58606449-689F90E8-BA06-40C9-914C-020A646E1022
P2860
EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
EGFRvIII-specific chimeric ant ...... nograft model of glioblastoma.
@ast
EGFRvIII-specific chimeric ant ...... nograft model of glioblastoma.
@en
type
label
EGFRvIII-specific chimeric ant ...... nograft model of glioblastoma.
@ast
EGFRvIII-specific chimeric ant ...... nograft model of glioblastoma.
@en
prefLabel
EGFRvIII-specific chimeric ant ...... nograft model of glioblastoma.
@ast
EGFRvIII-specific chimeric ant ...... nograft model of glioblastoma.
@en
P2093
P2860
P1433
P1476
EGFRvIII-specific chimeric ant ...... nograft model of glioblastoma.
@en
P2093
Bryan D Choi
Carter M Suryadevara
Elias J Sayour
Gabriel De Leon
Gary E Archer
Hongsheng Miao
James E Herndon
John H Sampson
Laura A Johnson
Luis Sanchez-Perez
P2860
P304
P356
10.1371/JOURNAL.PONE.0094281
P407
P577
2014-04-10T00:00:00Z